▲Wirig Diagram Hot
▲ ▲ ▼

Breast Tall Cell Carcinoma with Reverse Polarity

By

Breast tall cell carcinoma with reverse polarity (TCC-RP) is a rare and aggressive subtype of breast cancer, accounting for only about 1-2% of all invasive breast cancers. This subtype is characterized by tall columnar cells with reversed polarity, arranging in papillary or trabecular patterns. TCC-RP often presents diagnostic and therapeutic challenges due to its unique features, requiring careful understanding and management.

TCC-RP typically occurs in postmenopausal women, with a median age at diagnosis of around 70 years. Unlike other forms of breast cancer, it shows a predilection for the upper outer quadrant of the breast. It often presents as a palpable mass or skin thickening, with a higher likelihood of lymph node involvement and distant metastasis at the time of diagnosis.

Diagnosis of TCC-RP

Accurate diagnosis of TCC-RP is crucial due to its distinct clinical and pathological features, which can differentiate it from other breast cancers. Core needle biopsy is the primary diagnostic tool, allowing pathologists to analyze the unique architectural and cytological features of TCC-RP.

breast tall cell carcinoma with reverse polarity
breast tall cell carcinoma with reverse polarity
dcis-cancer – DCIS 411 | Ductal Carcinoma In Situ Education and Patient Resources
dcis-cancer – DCIS 411 | Ductal Carcinoma In Situ Education and Patient Resources
10-year study shows tomosynthesis improves breast cancer detection
10-year study shows tomosynthesis improves breast cancer detection

Immunohistochemical (IHC) stains can augment the diagnostic process by demonstrating the reversed polarity of the tall columnar cells. Nuclear expression of aminopeptidase-P (APP) and cysteine-rich 61 (CYR61) are often used as diagnostic markers, with 90-100% sensitivity and 85-95% specificity.

imagenology Findings

Imaging modalities, such as mammography, ultrasound, and magnetic resonance imaging (MRI), also play vital roles in diagnosing and staging TCC-RP. Mammography may show a high-density mass or asymmetric density, while ultrasound typically reveals a well-defined, hypoechoic, solid mass with posterior acoustic shadowing. MRI can help assess the extent of the tumor and detect any multifocal or multicentric disease.

25 Facts About Mucinous Carcinoma Of The Breast
25 Facts About Mucinous Carcinoma Of The Breast
Revealed, how breast density is key to cancer
Revealed, how breast density is key to cancer
☝
☝

Dynamic contrast-enhanced MRI can demonstrate typical characteristics of TCC-RP, including early and rapid contrast enhancement and washout kinetics.

Histopathological Features

Histologically, TCC-RP is characterized by tall columnar cells arranged in a papillary,cribe, or trabecular pattern, with reversed nuclear polarity. The cells have eosinophilic, koja-staining cytoplasm, and hyperchromatic, elongated nuclei. Mitotic figures and comedo-type necrosis can be frequent, reflecting the aggressive nature of the tumor.

TCC-RP often lacks the usual breast cancer immunohistochemical profile, showing loss of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This makes it distinct from other common breast cancer subtypes and influences treatment decisions.

Invasive Ductal Carcinoma of the Breast in a 27 Year Old
Invasive Ductal Carcinoma of the Breast in a 27 Year Old
Lobular Breast Cancer: Symptoms, Treatment, and Prognosis
Lobular Breast Cancer: Symptoms, Treatment, and Prognosis
Ductal Carcinoma, Invasive Ductal Carcinoma, Educational Benign Tumor Diagram, Normal Mammogram, Breast Ultrasound Image, Tumor Microenvironment Diagram, Fibroadenoma Breast, Dark Art Photography, Breast Projection
Ductal Carcinoma, Invasive Ductal Carcinoma, Educational Benign Tumor Diagram, Normal Mammogram, Breast Ultrasound Image, Tumor Microenvironment Diagram, Fibroadenoma Breast, Dark Art Photography, Breast Projection
Discovering breast cancer Biology, Pink
Discovering breast cancer Biology, Pink
CEACAM1-4S, a cell–cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture | PNAS
CEACAM1-4S, a cell–cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture | PNAS
Breast Cancer Types and Stages | MyBreastCancerTreatment.org Breast Root Types, Ductal Carcinoma, Ductal Carcinoma In Situ, Breast Health, Types Of Cancers
Breast Cancer Types and Stages | MyBreastCancerTreatment.org Breast Root Types, Ductal Carcinoma, Ductal Carcinoma In Situ, Breast Health, Types Of Cancers

Treatment and Prognosis of TCC-RP

The management of TCC-RP usually involves a multidisciplinary approach, with surgical and adjuvant systemic treatments playing crucial roles. Due to the rarity of this subtype, there are no randomized controlled trials specifically studying TCC-RP, and current treatments are largely extrapolated from those used for other breast cancer subtypes.

Surgery is the primary treatment modality, with total mastectomy being the preferred choice due to the high likelihood of multifocal and multicentric disease. Axillary staging is also crucial, as TCC-RP often presents with lymph node involvement. Lymph node dissection or sentinel lymph node biopsy is typically performed.

Adjuvant Systemic Therapy

Given the lack of expression of ER, PR, and HER2, hormonal therapy and anti-HER2 targeted therapies are generally not recommended for TCC-RP patients. Thus, chemotherapy remains the mainstay of systemic adjuvant treatment. The decision to offer chemotherapy is usually based on traditional prognostic factors such as tumor size, lymph node status, and histological grade.

The most common chemotherapy regimens used in the adjuvant setting include anthracycline and taxane-based regimens, as per current NCCN guidelines for infiltrating ductal carcinoma. However, given the rarity of TCC-RP, many patients may participate in clinical trials to optimize their treatment.

Clinical Outcomes and Prognosis

The prognosis of TCC-RP remains poor, primarily due to its aggressive behavior and high likelihood of distant metastasis. Patients typically present with advanced-stage disease and have a higher risk of recurrence and mortality compared to other breast cancer subtypes.

Elaborative studies on TCC-RP outcomes are limited due to its rarity. A retrospective study involving 40 patients with TCC-RP reported a 5-year disease-specific survival rate of 51% and a distant disease-free survival rate of 37%.

Despite these gloomy projections, early diagnosis and optimal multidisciplinary management can improve patient outcomes. Continued research into the molecular characteristics and pathogenesis of TCC-RP is crucial for developing novel targeted therapies and improving the prognosis of this aggressive breast cancer subtype.

In the future, with advanced technologies like liquid biopsy and artificial intelligence, we may be able to detect TCC-RP at an earlier stage, Personalized treatment plans can then be implemented, leading to improved patient outcomes. The journey ahead in managing TCC-RP is indeed complex but filled with promise."

💬 Comments ↗ Share ★ Save
AD